Bayer expands MIT genome collaboration
This article was originally published in Scrip
Executive Summary
Bayer and the Broad Institute of MIT and Harvard are hoping to create new cardiovascular treatments and diagnostics by expanding their collaboration in genomic research, which is currently focused on oncology. The collaboration combines Bayer's expertise in cardiology and the institute's genomics and biology knowhow. The two organizations will focus on genetic discovery, target validation, and drug discovery. A joint steering committee will oversee the collaboration and a joint research committee will supervise research progress and direction. Financial terms of the agreement have not been disclosed. Cardiovascular genomics is an emerging field of cardiology that uses genomic information to characterize disease risk and identify new therapeutic targets for drug discovery. Back in 2013 Bayer and the institute struck a five-year collaboration in oncogenomics and drug discovery.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.